Wanda Liguigli, Roberto Barbieri, R. Cengarle, Anita Rimanti, Giovanna Catania, Francesca Turina, Camilla Pesoni, Maurizio Cantore
{"title":"五线疗法治疗 ALK 阳性肺癌脑转移灶和脑膜转移灶患者的十年生存率:病例报告","authors":"Wanda Liguigli, Roberto Barbieri, R. Cengarle, Anita Rimanti, Giovanna Catania, Francesca Turina, Camilla Pesoni, Maurizio Cantore","doi":"10.29011/2574-7754.101711","DOIUrl":null,"url":null,"abstract":"Anaplastic lymphoma kinase (ALK) translocation is observed in 4–5% of lung adenocarcinoma patients. In October 2012, we diagnosed a translocated ALK lung adenocarcinoma with pleural and bone metastases in a 42-year-old woman. After 16 months of chemotherapy, due to progression of the abdominal lymph nodes, the patient started Crizotinib. After 28 months, brain MRI documented progression of brain disease and a CT scan showed lung progression. The patient underwent whole-brain radiotherapy and Ceritinib was started but discontinued after six months due to grade 3 gastrointestinal toxicity. In June 2017, progression of meningeal disease was documented and the patient started Brigatinib. After 41 months the brain CT scan showed multiple lesions and Lorlatinib was started. The patient is still continuing this therapy while maintaining a good quality of life. The advent of ALK inhibitors has changed the prognosis of these patients even in cases of cerebral and meningeal metastatic disease.","PeriodicalId":72213,"journal":{"name":"Annals of case reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ten Years Survival in a Patient with Brain and Meningeal Metastases from ALK-Positive Lung Cancer Treated with Five Lines of Therapy: A Case Report\",\"authors\":\"Wanda Liguigli, Roberto Barbieri, R. Cengarle, Anita Rimanti, Giovanna Catania, Francesca Turina, Camilla Pesoni, Maurizio Cantore\",\"doi\":\"10.29011/2574-7754.101711\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Anaplastic lymphoma kinase (ALK) translocation is observed in 4–5% of lung adenocarcinoma patients. In October 2012, we diagnosed a translocated ALK lung adenocarcinoma with pleural and bone metastases in a 42-year-old woman. After 16 months of chemotherapy, due to progression of the abdominal lymph nodes, the patient started Crizotinib. After 28 months, brain MRI documented progression of brain disease and a CT scan showed lung progression. The patient underwent whole-brain radiotherapy and Ceritinib was started but discontinued after six months due to grade 3 gastrointestinal toxicity. In June 2017, progression of meningeal disease was documented and the patient started Brigatinib. After 41 months the brain CT scan showed multiple lesions and Lorlatinib was started. The patient is still continuing this therapy while maintaining a good quality of life. The advent of ALK inhibitors has changed the prognosis of these patients even in cases of cerebral and meningeal metastatic disease.\",\"PeriodicalId\":72213,\"journal\":{\"name\":\"Annals of case reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29011/2574-7754.101711\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29011/2574-7754.101711","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ten Years Survival in a Patient with Brain and Meningeal Metastases from ALK-Positive Lung Cancer Treated with Five Lines of Therapy: A Case Report
Anaplastic lymphoma kinase (ALK) translocation is observed in 4–5% of lung adenocarcinoma patients. In October 2012, we diagnosed a translocated ALK lung adenocarcinoma with pleural and bone metastases in a 42-year-old woman. After 16 months of chemotherapy, due to progression of the abdominal lymph nodes, the patient started Crizotinib. After 28 months, brain MRI documented progression of brain disease and a CT scan showed lung progression. The patient underwent whole-brain radiotherapy and Ceritinib was started but discontinued after six months due to grade 3 gastrointestinal toxicity. In June 2017, progression of meningeal disease was documented and the patient started Brigatinib. After 41 months the brain CT scan showed multiple lesions and Lorlatinib was started. The patient is still continuing this therapy while maintaining a good quality of life. The advent of ALK inhibitors has changed the prognosis of these patients even in cases of cerebral and meningeal metastatic disease.